- PR Newswire•14 hours ago
JACKSONVILLE, Fla., April 28, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, has announced that on April 27, 2017, Dr. John Bonfiglio resigned as Chief Operating Officer, President and director of TapImmune, Inc. to pursue other opportunities. Speaking for the Board of Directors, Chairman and CEO of TapImmune Dr. Glynn Wilson stated, "We have been fortunate to have John serve the Company initially as a consultant and subsequently as an officer and director.
- Benzinga•2 days ago
The next generation of breast and ovarian cancer treatment is attacking the deadly disease from all angles. That is no more evident than in the glut of pharmaceutical companies racing to develop, test, ...
- Marketwired•10 days ago
NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...
TPIV : Summary for TAPIMMUNE INC - Yahoo Finance
TapImmune, Inc. (TPIV)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Ask||6.22 x 200|
|Day's Range||4.16 - 4.26|
|52 Week Range||3.32 - 9.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.95|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|